Bg pattern

Marixino 10 mg FILM-COATED TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use Marixino 10 mg FILM-COATED TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Marixino 10 mg Film-Coated Tablets EFG

Memantine Hydrochloride

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack:

  1. What is Marixino and what is it used for
  2. What you need to know before you take Marixino
  3. How to take Marixino
  4. Possible side effects
  5. Storing Marixino
  6. Contents of the pack and further information

1. What is Marixino and what is it used for

Marixino contains the active substance memantine hydrochloride. It belongs to a group of medicines called anti-dementia medicines. Memory loss in Alzheimer's disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that are involved in the transmission of important nerve signals in learning and memory. Marixino belongs to a group of medicines called NMDA receptor antagonists. Marixino acts on these receptors, improving the transmission of nerve signals and memory.

Marixino is used in the treatment of patients with moderate to severe Alzheimer's disease.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Marixino

Do not take Marixino

  • if you are allergic (hypersensitive) to memantine or any of the other ingredients of this medicine (listed in section 6)

Warnings and precautions

Consult your doctor or pharmacist before starting to take Marixino:

  • if you have a history of epileptic seizures.
  • if you have recently suffered a myocardial infarction (heart attack), if you suffer from congestive heart failure or if you have uncontrolled hypertension (high blood pressure).

In these situations, treatment should be carefully supervised and your doctor should regularly re-evaluate the clinical benefit of Marixino.

If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.

The use of memantine with other medicines such as amantadine (for the treatment of Parkinson's disease), ketamine (a medicine usually used as an anaesthetic), dextromethorphan (a medicine for the treatment of cough) and other NMDA antagonists should be avoided.

Children and adolescents

The use of Marixino in children and adolescents under the age of 18 is not recommended.

Using Marixino with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, the administration of Marixino may produce changes in the effects of the following medicines, so your doctor may need to adjust the dose:

  • amantadine, ketamine, dextromethorphan.
  • dantrolene, baclofen.
  • cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine.
  • hydrochlorothiazide (or any combination with hydrochlorothiazide).
  • anticholinergics (substances usually used to treat movement disorders or intestinal spasms).
  • anticonvulsants (substances used to prevent and eliminate convulsions).
  • barbiturates (substances usually used to induce sleep).
  • dopaminergic agonists (substances such as L-dopa, bromocriptine).
  • neuroleptics (substances used in the treatment of mental illnesses).
  • oral anticoagulants.

If you are admitted to hospital, inform your doctor that you are taking Marixino.

Taking Marixino with food and drinks

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from a normal diet to a strict vegetarian diet) or if you have renal tubular acidosis (RTA, excess of acid-producing substances in the blood due to kidney dysfunction or severe urinary tract infections), as your doctor may need to adjust the dose of the medicine.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy

The use of memantine is not recommended in pregnant women.

Breast-feeding

Women taking Marixino should stop breast-feeding.

Driving and using machines

Your doctor will inform you whether your illness allows you to drive or use machines safely. Also, Marixino may alter your reaction abilities, so driving or operating machinery may be inappropriate.

Marixino contains lactose and sodium

If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, i.e. it is essentially "sodium-free".

3. How to take Marixino

Follow exactly the administration instructions of this medicine given by your doctor. If you are unsure, ask your doctor or pharmacist.

Posology

The recommended dose of Marixino for adults and the elderly is 20 mg once a day. To reduce the risk of side effects, this dose is achieved gradually following the following daily scheme:

week 1

half a 10 mg tablet

week 2

one 10 mg tablet

week 3

one and a half 10 mg tablets

week 4

two 10 mg tablets

The normal starting dose is half a tablet once a day (1 x 5 mg) for the first week. It is increased to one tablet a day (1 x 10 mg) for the second week and to one and a half tablets once a day for the third week. From the fourth week onwards, the normal dose is two tablets once a day (1 x 20 mg).

Dosage for patients with renal insufficiency

If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should monitor your kidney function at specific intervals.

Administration

Marixino should be taken orally once a day. To get the most out of your medication, you should take it regularly every day and at the same time. The tablets should be swallowed with a little water. The 10 mg film-coated tablet can be divided into equal doses. The tablets can be taken with or without food.

Duration of treatment

Continue taking Marixino as long as it is beneficial for you. Your doctor should evaluate the effects of your treatment periodically.

If you take more Marixino than you should

  • Generally, taking too much Marixino should not harm you. You may experience an increase in the symptoms described in section 4 "Possible side effects".
  • If you take an overdose of Marixino, contact your doctor or seek medical advice, as you may need medical attention.

If you forget to take Marixino

  • If you realize you have forgotten to take your dose of Marixino, wait and take the next dose at the usual time.
  • Do not take a double dose to make up for the forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Generally, side effects are mild to moderate.

Common (may affect up to 1 in 10 people):

  • Headache, drowsiness, constipation, elevated liver function tests, dizziness, balance disorders, breathing difficulties, high blood pressure and hypersensitivity to the medicine.

Uncommon (may affect up to 1 in 100 people):

  • Fatigue, fungal infections, confusion, hallucinations, vomiting, gait disturbances, heart failure and formation of blood clots in the venous system (thrombosis/venous thromboembolism).

Rare (may affect up to 1 in 10,000 people)

  • Seizures.

Frequency not known (frequency cannot be estimated from the available data)

  • Pancreatitis, hepatitis and psychotic reactions.

Alzheimer's disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with memantine.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Marixino

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the blister and on the carton after EXP. The expiry date is the last day of the month stated.

No special storage conditions are required.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and further information

Composition of Marixino

  • The active substance is memantine hydrochloride.

Each film-coated tablet contains 10 mg of memantine hydrochloride, equivalent to 8.31 mg of memantine.

  • The other ingredients are:

Core of the tablet: lactose monohydrate, microcrystalline cellulose (E460), anhydrous colloidal silica, talc (E553b) and magnesium stearate (E470b).

Coating of the tablet: methacrylic acid-ethyl acrylate copolymer (1:1), sodium lauryl sulphate, polysorbate 80, talc (E553b), triacetin and simethicone.

See section 2 "Marixino contains lactose and sodium":

Appearance and packaging

Marixino film-coated tablets are biconvex, oval and white with a score line on one side (tablet width: 12.2-12.9 mm; thickness: 3.5-4.5 mm). The tablet can be divided into equal doses.

Marixino film-coated tablets are available in packs of 14, 28, 30, 42, 50, 56, 60, 70, 84, 90, 98, 100 and 112 film-coated tablets in blisters.

Not all pack sizes may be marketed.

Marketing authorisation holder

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturer

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

For further information about this medicine, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

KRKA Belgium, SA.

Tél/Tel: + 32 (0) 487 50 73 62

Lietuva

UAB KRKA Lietuva

Tel: + 370 5 236 27 40

Text in Bulgarian language with contact information of the company KRKA Bulgaria EOOD and its phone number

Luxembourg/Luxemburg

KRKA Belgium, SA.

Tél/Tel: + 32 (0) 487 50 73 62 (BE)

Ceská republika

KRKA CR, s.r.o.

Tel: + 420 (0) 221 115 150

Magyarország

KRKA Magyarország Kereskedelmi Kft.

Tel.: + 36 (1) 355 8490

Danmark

KRKA Sverige AB

Tlf: + 46 (0)8 643 67 66 (SE)

Malta

  • J. Busuttil Ltd.

Tel: + 356 21 445 885

Deutschland

TAD Pharma GmbH

Tel: + 49 (0) 4721 606-0

Nederland

KRKA Belgium, SA.

Tel: + 32 (0) 487 50 73 62 (BE)

Eesti

KRKA, d.d., Novo mesto Eesti filiaal

Tel: + 372 (0) 6 671 658

Norge

KRKA Sverige AB

Tlf: + 46 (0)8 643 67 66 (SE)

Ελλáδα

KRKA ΕΛΛΑΣ ΕΠΕ

Τηλ: + 30 2100101613

Österreich

KRKA Pharma GmbH, Wien

Tel: + 43 (0)1 66 24 300

España

KRKA Farmacéutica, S.L.

Tel: + 34 911 61 03 80

Polska

KRKA-POLSKA Sp. z o.o.

Tel.: + 48 (0)22 573 7500

France

KRKA France Eurl

Tél: + 33 (0)1 57 40 82 25

Portugal

KRKA Farmacêutica, Sociedade Unipessoal Lda.

Tel: + 351 (0)21 46 43 650

Hrvatska

KRKA - FARMA d.o.o.

Tel: + 385 1 6312 100

România

KRKA Romania S.R.L., Bucharest

Tel: + 4 021 310 66 05

Ireland

KRKA Pharma Dublin, Ltd.

Tel: + 353 1 413 3710

Slovenija

KRKA, d.d., Novo mesto

Tel: + 386 (0) 1 47 51 100

Ísland

LYFIS ehf.

Sími: + 354 534 3500

Slovenská republika

KRKA Slovensko, s.r.o.

Tel: + 421 (0) 2 571 04 501

Italia

KRKA Farmaceutici Milano S.r.l.

Tel: + 39 02 3300 8841

Suomi/Finland

KRKA Finland Oy

Puh/Tel: + 358 20 754 5330

Κúπρος

KI.PA. (PHARMACAL) LIMITED

Τηλ: + 357 24 651 882

Sverige

KRKA Sverige AB

Tel: + 46 (0)8 643 67 66 (SE)

Latvija

KRKA Latvija SIA

Tel: + 371 6 733 86 10

United Kingdom (Northern Ireland)

Consilient Health Limited

Tel: + 353 (0)1 2057760

Date of last revision of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency (EMA) website http://www.ema.europa.eu.

Online doctors for Marixino 10 mg FILM-COATED TABLETS

Discuss questions about Marixino 10 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (5)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
Camera Book a video appointment
€130
0.0 (1)
Doctor

Daria Portnova

Psychiatry 31 years exp.

Dr Daria Portnova is a psychiatrist and psychotherapist with over 30 years of clinical experience. She works with adults and adolescents aged 14 and over, providing online psychiatric and psychotherapeutic consultations.

In her practice, Dr Portnova supports patients facing the onset of mental health conditions, chronic psychiatric disorders, psychotic symptoms, trauma-related states, and complex emotional crises. Her work is structured and safety-focused, with an emphasis on stabilisation, accurate diagnosis, and long-term improvement in quality of life.

Patients consult Dr Daria Portnova for the following concerns:

  • existential crises and complex life situations;
  • loss, grief, and emotional exhaustion;
  • relationship difficulties, separation, and divorce;
  • psychological and psychiatric trauma, including complex PTSD (cPTSD);
  • anxiety disorders: generalised anxiety disorder and panic disorder;
  • social anxiety and social phobia;
  • obsessive-compulsive disorder (OCD);
  • sleep disorders;
  • depressive disorders;
  • bipolar affective disorder;
  • schizoaffective disorder;
  • schizophrenia;
  • personality disorders.
Dr Portnova combines psychiatric assessment with a psychotherapeutic approach. She works with evidence-based methods, including cognitive behavioural therapy (CBT) and third-wave approaches such as ACT, FACT, and CFT. Consultations are focused on clear clinical understanding, practical recommendations, and ongoing support over time.
Camera Book a video appointment
€110
5.0 (77)
Doctor

Sergey Ilyasov

Psychiatry 7 years exp.

Dr Sergey Ilyasov is an experienced neurologist and qualified psychiatrist who provides online consultations for adults and adolescents. Combining deep neurological expertise with a modern psychiatric approach, he ensures comprehensive diagnostics and effective treatment for a wide range of conditions affecting both physical and mental health.

Dr. Ilyasov helps patients in the following cases:

  • Chronic headaches (migraine, tension-type headache), back pain, neuropathic pain, dizziness, numbness in limbs, coordination disorders.
  • Anxiety disorders (panic attacks, generalized anxiety disorder), depression (including atypical and treatment-resistant forms), sleep disturbances (insomnia, hypersomnia, nightmares), stress, burnout.
  • Chronic pain syndromes and psychosomatic symptoms (e.g., irritable bowel syndrome related to stress, vegetative-vascular dystonia).
  • Behavioral disorders and concentration difficulties in adolescents (including ADHD, autism spectrum disorders), nervous tics.
  • Memory impairments, phobias, obsessive-compulsive disorder (OCD), emotional swings, and support for post-traumatic stress disorder (PTSD).

Thanks to his dual specialization in neurology and psychiatry, Dr Sergey Ilyasov offers integrated and evidence-based care for complex conditions requiring a multidisciplinary approach. His consultations focus on accurate diagnosis, development of an individualized treatment plan (including pharmacotherapy and psychotherapeutic methods), and long-term support adapted to each patient's unique needs.

Book an online consultation with Dr. Sergey Ilyasov to receive qualified assistance and improve your well-being today.

Camera Book a video appointment
€89
5.0 (137)
Doctor

Taisiia Proida

Psychiatry 7 years exp.

Dr. Taisiia Proida is a psychiatrist and cognitive behavioural therapist (CBT), and a member of the European Psychiatric Association. She offers online consultations for adults aged 18 and over, combining evidence-based medicine with an individualised approach to mental health care.

She specialises in consultations and ongoing support for a wide range of mental health concerns, including:

  • Mood disorders: depression, bipolar disorder, postpartum depression.
  • Anxiety disorders: generalised anxiety, OCD, panic attacks, phobias.
  • Post-traumatic stress disorder (PTSD) and complex PTSD.
  • Attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Assessment is provided only after an initial psychiatric evaluation and during a follow-up appointment.
  • Personality disorders and emotional instability.
  • Cyclothymia and mood fluctuations.
  • Schizophrenia spectrum and related conditions.

Dr. Proida combines clinical expertise with an empathetic approach, offering structured support based on evidence-based practices. Her work integrates CBT techniques with medical management, with a focus on anxiety and depressive disorders.

She works with clients from different countries and cultural backgrounds, adapting her communication style and recommendations to individual needs. With experience in international clinical trials (Pfizer, Merck), she values clarity, trust, and collaborative partnership in patient care.

Camera Book a video appointment
€120

Frequently Asked Questions

Is a prescription required for Marixino 10 mg FILM-COATED TABLETS?
Marixino 10 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in Marixino 10 mg FILM-COATED TABLETS?
The active ingredient in Marixino 10 mg FILM-COATED TABLETS is memantine. This information helps identify medicines with the same composition but different brand names.
Who manufactures Marixino 10 mg FILM-COATED TABLETS?
Marixino 10 mg FILM-COATED TABLETS is manufactured by Krka D.D. Novo Mesto. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of Marixino 10 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Marixino 10 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to Marixino 10 mg FILM-COATED TABLETS?
Other medicines with the same active substance (memantine) include AXURA 10 mg FILM-COATED TABLETS, AXURA 10 mg FILM-COATED TABLETS, AXURA 20 mg FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media